The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder

The first clinical trials with cannabidiol (CBD) as treatment for psychotic disorders have shown its potential as an effective and well-tolerated antipsychotic agent. However, the neurobiological mechanisms underlying the antipsychotic profile of CBD are currently unclear. Here we investigated the i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of psychiatric research 2023-07, Vol.163, p.93-101
Hauptverfasser:	van Boxel, Ruben, Gangadin, Shiral S., Janssen, Hella, van der Steur, Sanne, van der Vinne, Lucia J.C., Dortants, Lon, Pelgrim, Teuntje A.D., Draisma, Luc W.R., Tuura, Ruth, van der Meer, Pim, Batalla, Albert, Bossong, Matthijs G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticipation Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Brain Cannabidiol - adverse effects CBD Default mode network Glutamate Humans Magnetic Resonance Imaging - methods Psychosis Psychotic Disorders - diagnostic imaging Psychotic Disorders - drug therapy Schizophrenia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The first clinical trials with cannabidiol (CBD) as treatment for psychotic disorders have shown its potential as an effective and well-tolerated antipsychotic agent. However, the neurobiological mechanisms underlying the antipsychotic profile of CBD are currently unclear. Here we investigated the impact of 28-day adjunctive CBD or placebo treatment (600 mg daily) on brain function and metabolism in 31 stable recent-onset psychosis patients (
ISSN:	0022-3956 1879-1379
DOI:	10.1016/j.jpsychires.2023.05.019